Edwards Lifesciences (NYSE:EW) & Artivion (NYSE:AORT) Head to Head Comparison

Edwards Lifesciences (NYSE:EW) and Artivion (NYSE:AORT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Risk and Volatility

Edwards Lifesciences has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Artivion has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.

Valuation & Earnings

This table compares Edwards Lifesciences and Artivion”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$6.07 billion	10.02	$1.07 billion	$1.77	59.77
Artivion	$441.33 million	2.14	$9.77 million	($0.36)	-53.74

Edwards Lifesciences has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Edwards Lifesciences and Artivion, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	0	3	23	0	2.88
Artivion	1	0	6	0	2.71

Edwards Lifesciences currently has a consensus price target of $109.56, indicating a potential upside of 3.57%. Artivion has a consensus price target of $39.00, indicating a potential upside of 101.60%. Given Artivion’s higher probable upside, analysts plainly believe Artivion is more favorable than Edwards Lifesciences.

Profitability

This table compares Edwards Lifesciences and Artivion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	15.30%	16.06%	12.36%
Artivion	-3.65%	5.12%	2.36%

Institutional and Insider Ownership

79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 86.4% of Artivion shares are held by institutional investors. 0.3% of Edwards Lifesciences shares are held by insiders. Comparatively, 6.3% of Artivion shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Edwards Lifesciences beats Artivion on 10 of the 14 factors compared between the two stocks.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.

About Artivion

Artivion, Inc. is a medical device company focused on treating aortic disease and supporting cardiac and vascular surgery. Its products include aortic stent grafts and surgical grafts, mechanical heart valves, and BioGlue, a surgical adhesive used in cardiovascular procedures. The company was founded as CryoLife and adopted the Artivion name in 2022. It serves healthcare providers in the United States and international markets. Artivion is headquartered in Kennesaw, Georgia. Its chief executive officer is Pat Mackin.